Shopping Cart
- Remove All
- Your shopping cart is currently empty
Favipiravir is a potent and selective RNA-dependent RNA polymerase inhibitor for the treatment of influenza virus infections.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $41 | In Stock | |
10 mg | $57 | In Stock | |
50 mg | $82 | In Stock | |
100 mg | $124 | In Stock | |
500 mg | $315 | In Stock | |
1 mL x 10 mM (in DMSO) | $45 | In Stock |
Description | Favipiravir is a potent and selective RNA-dependent RNA polymerase inhibitor for the treatment of influenza virus infections. |
Targets&IC50 | RdRP:341 nM. |
In vitro | METHODS: RAW 264.7 cells were infected with MNV at an MOI of 0,001 using a T-705 dilution series (3.13-200 lg/mL). The MTS CPE reduction method was used to determine the antiviral activity of T-705 in the MNV/RAW 264.7 cell line. After 3 days of incubation, complete CPE was observed in the infected untreated cells. The cell culture supernatant was collected and analyzed by quantitative RT- PCR (qRT-PCR) quantitatively detects viral RNA load. RESULTS T-705 inhibited MNV-induced CPE (EC50: 39 ± 4 lg/mL [250 ± 11 lM]) and MNV RNA synthesis in cell culture (EC50: 19 ± 6 lg/mL [124 ± 42 lM]). [2] |
In vivo | METHODS: When Favipiravir (T-705) is used at a dose of 1-100mg/kg and infected with a lethal dose of influenza virus A/Victoria/3/75 (H3N2), A/Osaka/5/70 (H3N2) or A/ Duck/MN/1525/81 (H5N1) was administered orally 2 or 4 times a day to mice for 5 days, and the survival rate of the mice was observed. RESULTS Favipiravir (T-705) showed improved survival compared with placebo at doses of 30 mg/kg/day or higher, the drug was also administered at doses of 33 mg/kg/day or higher Provides significant protection against A/Duck/MN/1525/81 (H5N1) virus. [1] METHODS: Favipiravir was administered at 120 mg/kg/day or 200 mg/kg/day on days 1-5 after lethal SFTSV infection in type I interferon receptor knockout (IFNAR −/−) mice. (T-705) and continued for 5 days to observe the growth status of the mice. RESULTS All favipiravir-treated mice at doses of 120 mg/kg/day or 200 mg/kg/day, respectively, survived lethal SFTSV infection when treatment was initiated within 3 and 4 days of infection. [3] |
Cell Research | The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 103 cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO2. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).(Only for Reference) |
Alias | T-705, 6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide |
Molecular Weight | 157.1 |
Formula | C5H4FN3O2 |
Cas No. | 259793-96-9 |
Smiles | NC(=O)c1nc(F)cnc1O |
Relative Density. | 1.78 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||||||||||||
Solubility Information | Ethanol: 12 mg/mL (76.4 mM) H2O: 5 mg/mL (31.82 mM) DMSO: 45 mg/mL (286.44 mM) | |||||||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||||||||||||
H2O/Ethanol/DMSO
Ethanol/DMSO
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.